Shares jumped 56% on debut as the biotech advances oxnimbi, a once-nightly pill targeting an underlying cause of obstructive sleep apnea, toward a 2027 FDA decision.
Hebrew University researchers show that the overactive gene switches driving tumor growth physically strain and snap DNA — a stress point that might be turned against cancer.
By tracking some patients for up to 25 years, Sanger Institute researchers found DNA changes that flag which slow-growing blood cancers will progress — long before symptoms.
The Series C, backed by Eli Lilly and Bristol Myers Squibb, will advance a FAP-targeted radiotherapeutic for sarcoma and expand a pipeline of precision radioligand drugs.
The partnership pairs miRecule’s RNA-design platform with peptide-based delivery to reach tissues current RNA therapies struggle to treat, starting with neuromuscular disease.
The joint investment expands device assembly for Lilly’s KwikPen in the Cincinnati region, adding at least 400 jobs as demand for diabetes and obesity injectables surges.
A $200 million trim to sales guidance and signs that an early demand surge had normalized wiped out roughly $12 billion in market value, as competition in the heart-disease market intensifies.
A Science study traced nine stages of metastasis and found a quiet, immune-evading cell state that, when disrupted, let the immune system fight the spreading cancer.
A US compounding group is marketing an under-the-tongue, unapproved version of the weight-loss drug to private UK clinics — a practice Novo Nordisk says risks patient safety.
Johnson & Johnson pays $785 million upfront for an option to buy Flagship-backed Sail Biomedicines, whose nanoparticle-and-RNA platform aims to make CAR-T inside the body.
The all-stock reverse merger, paired with a $278 million private placement, creates a Nasdaq-listed company built around CLD-423 for inflammatory bowel disease.
LTG-001, an oral Nav1.8 blocker, eased post-surgical pain and cut opioid rescue use in a 343-patient trial published in the New England Journal of Medicine.